How a Specialty Pharma Company Mapped the Global Oncology Market and Built a Data-Driven Pipeline Strategy to Accelerate Commercial Growth
Executive Snapshot
Client
Situation/Challenge
Objective
Constancy Researchers Solution
Impact
Client Outcome
The Situation / Challenge
The global oncology pharmaceuticals market is one of the fastest-growing and most complex segments in the life sciences industry. Driven by rising cancer incidence, rapid advances in targeted therapies and immuno-oncology, accelerating biomarker-driven drug development, and evolving regulatory pathways, the market is expanding significantly — but also intensifying in competitive density across nearly every major tumour type.
The client — a mid-size specialty pharma company with a differentiated oncology pipeline — faced a critical strategic crossroads. It possessed genuine scientific capability across multiple therapy areas but lacked the structured market intelligence needed to confidently determine where to concentrate commercial investment, how large the addressable patient populations were, and which pipeline assets were best positioned to compete against increasingly well-funded incumbents and emerging biotech challengers.
Without a clear, evidence-based commercialisation strategy, the risk of misallocating capital across therapy areas — and entering markets already approaching competitive saturation — was substantial
Key challenges included:
- Insufficient market-level intelligence to prioritise pipeline investment across multiple competing oncology therapy areas
- Limited visibility into patient population sizing, treatment gap analysis, and payer landscape dynamics across target geographies
- Uncertainty around competitive intensity and market entry timing across crowded and emerging oncology sub-segments
- Absence of a structured commercial roadmap to sequence pipeline launches, partnership priorities, and market entry decisions
- Growing pressure from investors and board to demonstrate a commercially credible, evidence-backed growth strategy
- Diverging regulatory approval pathways and reimbursement landscapes across the US, EU, and emerging markets adding strategic complexity
Constancy Researchers Solution
Constancy Researchers deployed a two-phase engagement — beginning with a comprehensive suite of oncology market research reports to establish a rigorous evidence base, followed by a structured Strategy and Growth Advisory workstream to translate intelligence into a prioritised, investor-grade commercialisation roadmap. The engagement was built around one foundational question: Where does this company have the greatest opportunity to win, and in what sequence should it move?
1. Oncology Market Sizing & Therapy-Level Demand Analysis
- Delivered market research reports covering total addressable market sizing across six oncology therapy areas including solid tumours, haematological malignancies, and immuno-oncology.
- Quantified diagnosed patient populations, treatment rates, therapy penetration gaps, and multi-year revenue growth forecasts by indication, geography, and line of therapy — identifying where unmet clinical need most significantly exceeded current commercial supply.
2. Competitive Pipeline & Commercial Landscape Benchmarking
- Mapped active clinical pipelines, approved therapies, and late-stage development programmes across global incumbent pharma groups, emerging biotech challengers, and academic spinouts.
- Benchmarked mechanism of action differentiation, clinical trial positioning, pricing and reimbursement strategies, and launch sequencing — identifying where the client’s pipeline had genuine competitive differentiation versus areas of high crowding risk.
3. Payer, Reimbursement & Market Access Intelligence
- Assessed payer coverage frameworks, health technology assessment processes, and reimbursement decision criteria across the US, key EU5 markets, and select Asia-Pacific geographies.
- Identified therapy areas with the most favourable market access conditions relative to clinical differentiation requirements — enabling realistic commercial revenue modelling and go-to-market timing decisions.
4. Pipeline Prioritisation & Opportunity Scoring Framework
- Developed a structured prioritisation matrix scoring each pipeline asset and therapy area against market size, competitive differentiation, regulatory pathway clarity, payer receptivity, and strategic fit with the client’s commercial capabilities.
- Distinguished between lead programmes ready for accelerated commercialisation investment, partnership candidates, and assets warranting divestment or deprioritisation.
5. Commercial Growth Strategy & Multi-Year Roadmap Design
- Translated market intelligence into a phased, multi-year commercial strategy covering launch sequencing, geographic entry prioritisation, partnership and licensing opportunity identification, commercial capability build requirements, and investor communication frameworks.
- Developed a board-ready strategic narrative with quantified revenue scenarios and risk-adjusted growth projections to align leadership and secure investment commitment.
This integrated approach — combining deep oncology market intelligence with structured commercial advisory — ensured the client moved from scientific ambition to strategic clarity with the evidence base needed to drive confident, board-aligned decision-making.
Impact
- Sized a combined addressable oncology market opportunity exceeding USD 14 billion across six therapy areas and four target geographies
- Revealed significant treatment gaps in second- and third-line therapy settings where the client’s pipeline mechanisms showed the strongest clinical differentiation
- Mapped payer receptivity and market access conditions across 12 markets, identifying the US and Germany as highest-priority initial launch geographies
- Surfaced three licensing and co-commercialisation partnership opportunities with strategic rationale, accelerating the business development pipeline
- Identified two high-growth, competitively underpenetrated therapy segments — targeted solid tumour therapy and next-generation haematology — as priority commercial entry points
- Benchmarked five lead pipeline assets against global competitor programmes, identifying three with clear differentiation advantages and two with high crowding risk
- Delivered a risk-adjusted revenue model projecting commercialisation scenarios across conservative, base, and accelerated growth pathways
- Shifted leadership from fragmented, asset-by-asset decision-making to a unified, portfolio-level commercial strategy with clear priorities and investment sequencing
Client Outcome
Pipeline Priorities
Realigned toward the two highest-opportunity oncology therapy segments, reducing capital disper-sion across lower-priority assets.
Commercial Market Entry
Launched a phased entry into targeted solid tumour and next-generation haematology segments with a sequenced, geography-by-geography market activation plan.
Partnership Progress
Initiated structured discussions with two strategic licensing candidates identified through the com-petitive landscape benchmarking workstream.
Growth Investment
Secured board and investor approval for a three-year commercial growth plan anchored in market intelligence evidence and advisory recommendations.
Market Access Readiness
Proactively addressed payer requirement gaps identified during the reimbursement intelligence as-sessment
Cross-Functional Alignment
Unified clinical development, regulatory, commercial, and finance teams around a shared, data-backed strategic growth narrative.
Strategic Risk Reduction
Deprioritised two high-crowding pipeline programmes, freeing capital and commercial bandwidth for the highest-differentiation assets.
Ongoing Intelligence Capability
Built a repeatable market intelligence and strategy review cadence enabling continuous competi-tive monitoring, regulatory tracking, and commercial recalibration.
Market Positioning
Established as a commercially credible, insight-led specialty pharma player capable of competing with discipline and speed in a complex, rapidly evolving global oncology market.
Case Studies
Learn how our success stories power data-driven growth across industries
How a Tier-2 Semiconductor Manufacturer Used Customized Research and Data Analytics to Decode Microchip Demand, Sharpen Competitive Positioning, and Redirect Investment Toward High-Growth Verticals
Executive Snapshot Client Tier-2 Semiconductor & Microchip Manufacturer, East Asia...
Read MoreHow a Global Building Materials Manufacturer Used Market Research Reports to Redirect Investment, Exit Declining Segments, and Capture High-Growth Construction Demand
Executive Snapshot Client Global Building Materials Manufacturer & Supplier, Europe...
Read MoreHow a Multi-Category Consumer Goods Company Uncovered Shifting Consumer Demand and Built a VoC-Led Consulting Strategy to Reignite Portfolio Growth
Executive Snapshot Client Multi-Category Consumer Goods Company, Western Europe &...
Read More